A lower qPCR cycle count can indicate more starting target material, but “more” needs a denominator. More target per reaction, more target relative to a reference transcript and more target per cell are different claims.
The AAMC content outline includes PCR, gels, cDNA and gene-expression analysis. The qPCR examples below apply those foundations to passage reasoning; they do not imply that every analytical detail is a separately specified exam requirement. All data are original teaching examples.
First identify what the assay actually starts with
PCR amplifies DNA. To investigate an RNA transcript, researchers can first use reverse transcription to produce complementary DNA, then amplify that cDNA. In RT-qPCR, RT refers to reverse transcription, while qPCR refers to monitoring amplification quantitatively during cycling.
A conventional endpoint gel separates DNA fragments, with smaller linear fragments generally migrating farther under comparable gel conditions. A band near the expected size supports a size observation; it does not by itself establish the exact sequence or the original number of RNA molecules. OpenStax introduces PCR and gel methods.
Consider an assay expected to produce a 180-base-pair product. A sample lane contains a single band near 180 bp. That is compatible with the intended product. A different sequence of similar length could also migrate there, however. Specificity needs additional assay evidence, rather than simply relabeling an expected-size band “confirmed identity.”
Endpoint band brightness is also not automatically proportional to starting transcript abundance. Reactions may have reached different amplification limits, and loading and detection conditions can differ. A passage must supply a justified quantitative framework before a brightness comparison supports a numerical expression ratio.
Use controls that address this assay’s alternatives
Suppose the 180-bp band appears in an RNA-derived sample and also in the same sample processed without reverse transcriptase. The no-template control remains blank.
The blank no-template control argues against detectable contamination introduced through shared reaction components under these conditions. It does not exclude DNA already present in the sample. The no-RT product means amplification did not require the reverse-transcription step, undermining the claim that the sample signal specifically measures RNA-derived cDNA.
Residual genomic DNA or other amplifiable DNA is a plausible explanation. The band alone does not identify which contaminant or product is responsible. An assay design that distinguishes cDNA from genomic products can help, but its effectiveness depends on the gene structure and primer placement.
A positive amplification control addresses whether the assay can produce a signal from a known suitable template. It does not automatically rule out inhibition unique to the experimental sample. The MIQE précis discusses no-RT controls, no-template controls, inhibition checks and assay validation. Each addresses a particular alternative; none makes all the others redundant.
Worked example: derive the normalized fold change
A quantification cycle, often written Cq or Ct, identifies where amplification signal crosses a specified threshold. Within one validated assay, assume a constant amplification factor A per cycle over the relevant exponential region. If threshold signal is proportional to a fixed product quantity, then:
starting quantity × A^Ct = threshold quantity.
For that assay, comparing treated with control gives:
treated/control starting-quantity ratio = A^(Ctcontrol − Cttreated).
This shows why an earlier threshold corresponds to more starting material under the model. It also shows where the efficiency assumption enters. Pfaffl’s original relative-quantification method explicitly accounts for amplification efficiency and reference-transcript normalization.
Consider these illustrative results:
| Sample | Target Ct | Reference Ct |
|---|---|---|
| Control | 24 | 20 |
| Treated | 22 | 19 |
Assume both assays double each cycle, use comparable within-assay threshold analysis, remain in their validated measurement ranges, and show no relevant inhibition or contamination. Also assume the reference is validated as stable for the intended biological comparison, with extraction and reverse transcription sufficiently comparable or appropriately controlled.
For the target, treated/control input is 2^(24−22) = 4. For the reference, it is 2^(20−19) = 2. The target-to-reference ratio therefore changes by 4/2 = 2-fold.
Equivalently, ΔCt = Cttarget − Ctreference is 4 for control and 3 for treated. ΔΔCt = 3 − 4 = −1, so 2^(−ΔΔCt) = 2.
The raw target result of fourfold is not the normalized result. The reference shift indicates that the reactions are not directly comparable on raw target Ct alone. The biological interpretation still depends on why that reference is appropriate.
Equal efficiency is an assumption, not a label
Now keep the same Ct table but suppose the target amplification factor is 1.8 and the reference factor is 2.0, both measured and stable across the compared samples. A factor of 1.8 means an 80% increase per cycle, not 180% efficiency.
The normalized ratio becomes:
1.8^(24−22) / 2.0^(20−19) = 3.24/2 = 1.62-fold.
Blindly applying 2^(−ΔΔCt) would still return twofold and would ignore the supplied efficiency information. If both factors were 1.9, the corresponding result would be 1.9-fold, rather than twofold.
These calculations compare changes within each assay before normalizing. A target Ct of 24 and reference Ct of 20 do not, by themselves, establish an absolute sixteenfold difference in their transcript numbers: assays can have different signal properties and calibration relationships.
Normalization cannot repair an invalid biological reference
Calling a gene a “housekeeping gene” does not prove that treatment leaves it stable. MIQE recommends validating reference suitability for the particular experimental setting. The single-reference example here assumes that validation; it is not a blanket recommendation to use one reference gene.
Even a technically sound target/reference ratio is not automatically a per-cell result. Changes in tissue cell composition or RNA content can alter the interpretation. And a single illustrative Ct table supplies neither biological variability nor statistical significance. Repeated wells estimate technical repeatability; they do not replace independent biological samples.
Transfer exercise: three cycles earlier in both assays
A new control sample has target Ct 25 and reference Ct 21. A treated sample has target Ct 22 and reference Ct 18. Assume both assays double each cycle and all the validity conditions above hold.
The target shifts three cycles earlier, giving an eightfold raw input ratio. The reference also shifts three cycles earlier, giving an eightfold ratio. The normalized target/reference change is 8/8 = 1: no change in that measured ratio.
“Eightfold gene-expression increase” ignores normalization. “The treatment cannot affect any RNA” extends one normalized measurement to every transcript and mechanism. “The samples contain exactly the same number of cells” introduces a denominator never measured.
If the treated sample also has a substantial no-RT signal, the arithmetic remains calculable but the RNA-expression interpretation is not validated. A formula cannot distinguish cDNA from contaminating template by itself.
Read the next assay in three layers
Identify the starting material, determine which alternatives the controls address, and then write the quantity and denominator the calculation estimates. Finish with a sentence that states the result at that level of specificity. This keeps a visible band or a tidy fold change from becoming a stronger biological claim than the experiment supports.